Literature DB >> 26418342

Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.

Neetu Singh1, Lisbeth Ramĩrez-Carvajal1,2, Teresa de Los Santos3, Michael C Golding1, Charles R Long1.   

Abstract

The genetic regulatory network controlling the innate immune system is well understood in many species. However, the role of the epigenetic mechanisms underlying the expression of immunoregulatory genes is less clear, especially in livestock species. Histone H3 lysine 9 dimethylation (H3K9me2) is an epigenetic modification associated with transcriptional silencing within the euchromatin regions. Euchromatic histone-lysine N-methyltransferase 2 (EHMT2; also known as G9a) is a crucial enzyme responsible for regulating the dynamics of this epigenetic modification. It has been shown that histone modifications play a role in regulating type I interferon (IFN) response. In the present study, we investigated the role of EHMT2 in the epigenetic regulation of bovine antiviral innate immunity and explored its therapeutic potential against viral infections. We evaluated the effects of pharmacological and RNAi-mediated inhibition of EHMT2 on the transcription of IFN-β and other IFN-inducible antiviral genes, as well as its effect on foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) replication in bovine cells. We show that treatment of primary bovine cells with the synthetic EHMT2 inhibitor (UNC0638) either before or shortly after virus infection resulted in a significant increase in transcript levels of bovine IFN-β (boIFN-β; 300-fold) and other IFN-inducible genes, including IFN-stimulated gene 15 (ISG-15), myxovirus resistance 1 (Mx-1), Mx-2, RIG-I, 2',5'-oligoadenylate synthetase 1 (OAS-1), and protein kinase R (PKR). Expression of these factors correlated with a significant decrease in VSV and FMDV viral titers. Our data confirm the involvement of EHMT2 in the epigenetic regulation of boIFN-β and demonstrate the activation of a general antiviral state after EHMT2 inhibition.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26418342      PMCID: PMC4722570          DOI: 10.1089/jir.2015.0006

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Multiple epigenetic modifiers induce aggressive viral extinction in extraembryonic endoderm stem cells.

Authors:  Michael C Golding; Liyue Zhang; Mellissa R W Mann
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

3.  SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state.

Authors:  Steve Bilodeau; Michael H Kagey; Garrett M Frampton; Peter B Rahl; Richard A Young
Journal:  Genes Dev       Date:  2009-11-01       Impact factor: 11.361

4.  Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294.

Authors:  Kenichi Imai; Hiroaki Togami; Takashi Okamoto
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

Review 5.  Emerging role of ISG15 in antiviral immunity.

Authors:  Brian Skaug; Zhijian J Chen
Journal:  Cell       Date:  2010-10-15       Impact factor: 41.582

6.  Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex.

Authors:  Anne Schaefer; Srihari C Sampath; Adam Intrator; Alice Min; Tracy S Gertler; D James Surmeier; Alexander Tarakhovsky; Paul Greengard
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

7.  Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.

Authors:  Fayna Diaz-San Segundo; Mauro P Moraes; Teresa de Los Santos; Camila C A Dias; Marvin J Grubman
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

8.  Essential role of the histone methyltransferase G9a in cocaine-induced plasticity.

Authors:  Ian Maze; Herbert E Covington; David M Dietz; Quincey LaPlant; William Renthal; Scott J Russo; Max Mechanic; Ezekiell Mouzon; Rachael L Neve; Stephen J Haggarty; Yanhua Ren; Srihari C Sampath; Yasmin L Hurd; Paul Greengard; Alexander Tarakhovsky; Anne Schaefer; Eric J Nestler
Journal:  Science       Date:  2010-01-08       Impact factor: 47.728

Review 9.  Rhabdovirus evasion of the interferon system.

Authors:  Martina Rieder; Karl-Klaus Conzelmann
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

10.  Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells.

Authors:  Yutaka Kondo; Lanlan Shen; Saira Ahmed; Yanis Boumber; Yoshitaka Sekido; Bassem R Haddad; Jean-Pierre J Issa
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

View more
  3 in total

Review 1.  Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response.

Authors:  Miguel Rodríguez Pulido; Margarita Sáiz
Journal:  Front Cell Infect Microbiol       Date:  2017-06-13       Impact factor: 5.293

Review 2.  RNA-Seq Revealed a Circular RNA-microRNA-mRNA Regulatory Network in Hantaan Virus Infection.

Authors:  Shuang Lu; Ni Zhu; Weiwei Guo; Xin Wang; Kaiji Li; Jie Yan; Cuiping Jiang; Shiyu Han; Hanmin Xiang; Xiaohan Wu; Yuanyuan Liu; Hairong Xiong; Liangjun Chen; Zuojiong Gong; Fan Luo; Wei Hou
Journal:  Front Cell Infect Microbiol       Date:  2020-03-13       Impact factor: 5.293

Review 3.  The Different Tactics of Foot-and-Mouth Disease Virus to Evade Innate Immunity.

Authors:  Gisselle N Medina; Fayna Díaz-San Segundo; Carolina Stenfeldt; Jonathan Arzt; Teresa de Los Santos
Journal:  Front Microbiol       Date:  2018-11-12       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.